Kyowa Kirin
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.
Headquarters in Otemachi, Chiyoda, Tokyo | |
| Company type | Public (K.K) |
|---|---|
Traded as | TYO: 4151 Nikkei 225 Component |
| Industry |
|
| Founded | July 1, 1949 |
| Headquarters | Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan |
Key people | Nobuo Hanai, (CEO and President) |
| Products |
|
| Revenue | $ 2.99 billion USD (FY 2022) (¥ 398.4 billion JPY) (FY 2022) |
Net income | $ 375 million USD (FY 2022) (¥ 53.6 billion JPY) (FY 2022) |
Number of employees | 7,532 (consolidated) (as of December 31, 2017) |
| Parent | Kirin Holdings Company, Limited |
| Subsidiaries | 47 (33 in Japan and 14 overseas countries) |
| Website | Official website |
| Footnotes / references | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.